<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1142"/><api:result><api:object category="publication" id="1142" last-affected-when="2024-04-01T00:52:10.717+01:00" last-modified-when="2024-04-01T00:52:10.717+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1142" created-when="2010-05-17T13:47:32.3+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-11-20</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1518216" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1002/1097-0142(20000615)88:12+&lt;3022::AID-CNCR19&gt;3.0.CO;2-R" last-modified-when="2022-09-11T05:55:26.277+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Kanis</api:last-name><api:initials>JA</api:initials><api:first-names>John A</api:first-names><api:separate-first-names><api:first-name>John</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2103" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2103"/></api:links><api:last-name>McCloskey</api:last-name><api:initials>EV</api:initials><api:first-names>Eugene V</api:first-names><api:separate-first-names><api:first-name>Eugene</api:first-name><api:first-name>V</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1097-0142</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>S12</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3022</api:begin-page><api:end-page>3032</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wiley</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1002/1097-0142(20000615)88:12+%3C3022::aid-cncr19%3E3.0.co;2-r</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>1</api:day><api:month>7</api:month><api:year>2021</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Bisphosphonates in multiple myeloma</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="96516" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0034659875" last-modified-when="2021-11-23T23:30:25.417+00:00"><api:citation-count>47</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>BACKGROUND. Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures. Hypercalcaemia is a common presenting feature but less common after adequate chemotherapy. These complications are caused by progressive focal and generalized osteolysis due, in turn, to increased activation of osteoclasts by osteoclast activating factors. These include tumor neorosis factor-Î², interleukin-1, and interleukin-6. The knowledge that disturbed bone remodeling is due to the activation of authentic osteoclasts provides the rationale for the use of bisphosphonates in myelomatosis. METHODS. This article reviews the place of bisphosphonates in the management of myeloma. RESULTS. There is good evidence that hypercalcaemia can be corrected with intravenous or oral bisphosphonates, and they are now the specific treatment of choice. Several studies have shown that their intravenous administration is beneficial in the acute management of bone pain due to malignancy, but studies in myelomatosis are lacking. In contrast, a number of well designed controlled studies have shown significant effects of long term treatment with clodronate and pamidronate to decrease the incidence of skeletal complications in myelomatosis. Benefits reported are a decreased incidence of bone pain, hypercalcaemia, vertebral and long-bone fractures, and the extension of osteolytic lesions. There may be a beneficial effect on survival, but this is much less certain. CONCLUSIONS. These agents provide a valuable adjunct to the management of myelomatosis. (C) 2000 American Cancer Society.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Kanis</api:last-name><api:initials>JA</api:initials><api:first-names>JA</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The Sheffield Medical School</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7102759272</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2103" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2103"/></api:links><api:last-name>McCloskey</api:last-name><api:initials>EV</api:initials><api:first-names>EV</api:first-names><api:separate-first-names><api:first-name>E</api:first-name><api:first-name>V</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The Sheffield Medical School</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">56134366000</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898347</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 SUPPL.</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3022</api:begin-page><api:end-page>3032</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Bisphosphonates in multiple myeloma</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Conference Proceeding</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="1142" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10898347" last-modified-when="2020-04-29T06:11:04.13+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>BACKGROUND: Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures. Hypercalcaemia is a common presenting feature but less common after adequate chemotherapy. These complications are caused by progressive focal and generalized osteolysis due, in turn, to increased activation of osteoclasts by osteoclast activating factors. These include tumor necrosis factor-beta, interleukin-1, and interleukin-6. The knowledge that disturbed bone remodeling is due to the activation of authentic osteoclasts provides the rationale for the use of bisphosphonates in myelomatosis. METHODS: This article reviews the place of bisphosphonates in the management of myeloma. RESULTS: There is good evidence that hypercalcaemia can be corrected with intravenous or oral bisphosphonates, and they are now the specific treatment of choice. Several studies have shown that their intravenous administration is beneficial in the acute management of bone pain due to malignancy, but studies in myelomatosis are lacking. In contrast, a number of well designed controlled studies have shown significant effects of long term treatment with clodronate and pamidronate to decrease the incidence of skeletal complications in myelomatosis. Benefits reported are a decreased incidence of bone pain, hypercalcaemia, vertebral and long-bone fractures, and the extension of osteolytic lesions. There may be a beneficial effect on survival, but this is much less certain. CONCLUSIONS: These agents provide a valuable adjunct to the management of myelomatosis.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Kanis</api:last-name><api:initials>JA</api:initials><api:first-names>JA</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Centre for Metabolic Bone Diseases at Sheffield (World Health Organization Collaborating Centre), University of Sheffield Medical School, United Kingdom.</api:line></api:address></api:addresses></api:person><api:person><api:links><api:link type="elements/user" id="2103" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2103"/></api:links><api:last-name>McCloskey</api:last-name><api:initials>EV</api:initials><api:first-names>EV</api:first-names><api:separate-first-names><api:first-name>E</api:first-name><api:first-name>V</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10898347</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 Suppl</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Clodronic Acid</api:keyword><api:keyword scheme="mesh">Diphosphonates</api:keyword><api:keyword scheme="mesh">Etidronic Acid</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Hypercalcemia</api:keyword><api:keyword scheme="mesh">Multiple Myeloma</api:keyword><api:keyword scheme="mesh">Pain</api:keyword><api:keyword scheme="mesh">Pamidronate</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>United States</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3022</api:begin-page><api:end-page>3032</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3022::AID-CNCR19&gt;3.0.CO;2-R</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>27</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Bisphosphonates in multiple myeloma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="882262" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10898347" last-modified-when="2021-01-19T17:57:11.787+00:00"><api:citation-count>26</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;h4&gt;Background&lt;/h4&gt;Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures. Hypercalcaemia is a common presenting feature but less common after adequate chemotherapy. These complications are caused by progressive focal and generalized osteolysis due, in turn, to increased activation of osteoclasts by osteoclast activating factors. These include tumor necrosis factor-beta, interleukin-1, and interleukin-6. The knowledge that disturbed bone remodeling is due to the activation of authentic osteoclasts provides the rationale for the use of bisphosphonates in myelomatosis.&lt;h4&gt;Methods&lt;/h4&gt;This article reviews the place of bisphosphonates in the management of myeloma.&lt;h4&gt;Results&lt;/h4&gt;There is good evidence that hypercalcaemia can be corrected with intravenous or oral bisphosphonates, and they are now the specific treatment of choice. Several studies have shown that their intravenous administration is beneficial in the acute management of bone pain due to malignancy, but studies in myelomatosis are lacking. In contrast, a number of well designed controlled studies have shown significant effects of long term treatment with clodronate and pamidronate to decrease the incidence of skeletal complications in myelomatosis. Benefits reported are a decreased incidence of bone pain, hypercalcaemia, vertebral and long-bone fractures, and the extension of osteolytic lesions. There may be a beneficial effect on survival, but this is much less certain.&lt;h4&gt;Conclusions&lt;/h4&gt;These agents provide a valuable adjunct to the management of myelomatosis.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Centre for Metabolic Bone Diseases at Sheffield (World Health Organization Collaborating Centre), University of Sheffield Medical School, United Kingdom.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Kanis</api:last-name><api:initials>JA</api:initials><api:first-names>JA</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2103" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2103"/></api:links><api:last-name>McCloskey</api:last-name><api:initials>EV</api:initials><api:first-names>EV</api:first-names><api:separate-first-names><api:first-name>E</api:first-name><api:first-name>V</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1097-0142</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898347</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>12 Suppl</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Multiple Myeloma</api:keyword><api:keyword scheme="mesh">Pain</api:keyword><api:keyword scheme="mesh">Hypercalcemia</api:keyword><api:keyword scheme="mesh">Diphosphonates</api:keyword><api:keyword scheme="mesh">Clodronic Acid</api:keyword><api:keyword scheme="mesh">Etidronic Acid</api:keyword><api:keyword scheme="mesh">Pamidronate</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3022</api:begin-page><api:end-page>3032</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>18</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Bisphosphonates in multiple myeloma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record><api:record format="native" id="2475589" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1035501488" last-modified-when="2024-04-01T00:52:10.72+01:00"><api:citation-count>41</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Kanis</api:last-name><api:initials>JA</api:initials><api:first-names>John A</api:first-names><api:separate-first-names><api:first-name>John</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0663427426.32</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2103" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2103"/></api:links><api:last-name>McCloskey</api:last-name><api:initials>EV</api:initials><api:first-names>Eugene V</api:first-names><api:separate-first-names><api:first-name>Eugene</api:first-name><api:first-name>V</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0766756074.39</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r</api:text><api:links><api:link type="doi" href="http://doi.org/10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1002/1097-0142(20000615)88:12+&lt;3022::aid-cncr19&gt;3.0.co;2-r"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10898347</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>6.75</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0008-543X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>S12</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc">Chronic Pain</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Pain Research</api:keyword><api:keyword scheme="rcdc">Hematology</api:keyword><api:keyword scheme="hrcs-hc">Musculoskeletal</api:keyword><api:keyword scheme="mesh">Clodronic Acid</api:keyword><api:keyword scheme="mesh">Diphosphonates</api:keyword><api:keyword scheme="mesh">Etidronic Acid</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Hypercalcemia</api:keyword><api:keyword scheme="mesh">Multiple Myeloma</api:keyword><api:keyword scheme="mesh">Pain</api:keyword><api:keyword scheme="mesh">Pamidronate</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>20</api:day><api:month>11</api:month><api:year>2000</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>3022</api:begin-page><api:end-page>3032</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>15</api:day><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wiley</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.7</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Bisphosphonates in multiple myeloma</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>88</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Clodronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Diphosphonates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Etidronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Hypercalcemia</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Multiple Myeloma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Pain</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Pamidronate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Multiple Myeloma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Pain</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Hypercalcemia</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Diphosphonates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Clodronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Etidronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Pamidronate</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Chronic Pain</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Pain Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hematology</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Musculoskeletal</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Clodronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Diphosphonates</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Etidronic Acid</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Hypercalcemia</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Multiple Myeloma</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Pain</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Pamidronate</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for" origin="issn-inferred">1117 Public Health and Health Services</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">4206 Public health</api:keyword></api:keywords></api:all-labels><api:journal issn="0008-543X" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973688" title="Cancer"><api:records><api:record source-name="summary"><api:title>Cancer</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1142/relationships"/></api:object></api:result></api:response>